RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis-Reference-Cited by-同舟云学术

RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis

Published:2023-09-22 Issue:5 Volume:26 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Tsantikidi Aikaterini¹,Papazisis Konstantinos²,Floros Theofanis³,Gazouli Maria⁴,Papadopoulou Eirini¹,Tsaousis Georgios¹,Nasioulas Georgios¹,Mester Andra⁵,Milan Kubelac⁵,Gozman Bogdan⁶,Afrasanie Vlad⁶,Stanculeanu Dana⁷,Trifanescu Oana⁷,Pescaru Florentina⁸,Militaru Claudia⁹,Papadimitriou Christos¹⁰

Affiliation:

1. Genekor Medical S.A., Gerakas, 15344 Athens, Greece

2. Department of Oncology, Euromedica General Clinic, 54645 Thessaloniki, Greece

3. Department of Oncology, Athens Naval and Veterans Hospital, 11521 Athens, Greece

4. Department of Basic Medical Sciences National, Kapodistrian University of Athens, 11527 Athens, Greece

5. Oncological Institute, 400015 Cluj‑Napoca, Romania

6. Regional Institute of Oncology, 700483 Iasi, Romania

7. Bucharest Oncological Institute, 700483 Bucuresti, Romania

8. St. Constantine Hospital, 500091 Brasov, Romania

9. Medisprof Cluj‑Napoca, 400641 Cluj‑Napoca, Romania

10. Second Department of Surgery, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11528, Greece

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference30 articles.

1. Advances in synthetic lethality for cancer therapy: Cellular mechanism and clinical translation;Topatana;J Hematol Oncol,2020

2. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2);Swisher;Nat Commun,2021

3. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer;Konstantinopoulos;Cancer Discov,2015

4. Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1/ENGOT-ov25 trial;Pujade-Lauraine;JCO Precis Oncol,2023

5. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer;Miller;Ann Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study;International Journal of Molecular Sciences;2024-05-11

2. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer;Cancers;2023-11-22